Guhan Pharmaceutical Group Co

Guhan Pharmaceutical Group Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Guhan Pharmaceutical Group Co (000590.SZ) as of Oct 30, 2026 is 39.29 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 11.73 % — a change of 235.05% (higher).

FCF Conversion

39.29 %

YoY

235.05%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Guhan Pharmaceutical Group Co is 2025 39.29 % . FCF Conversion Rate (FCF/EBITDA) of Guhan Pharmaceutical Group Co was 2024 11.73 % . It decreases by 235.05% higher compared to the previous year.

The Guhan Pharmaceutical Group Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
57.44 CNY
Jan 1, 2019
-15.63 CNY
Jan 1, 2020
77.35 CNY
Jan 1, 2021
-1.92 CNY
Jan 1, 2022
197.62 CNY
Jan 1, 2023
-199.78 CNY
Jan 1, 2024
11.73 CNY
Jan 1, 2025
39.29 CNY
The Guhan Pharmaceutical Group Co FCF Conversion history
YEARFCF ConversionYoY
39.29 %+235.05%
11.73 %-105.87%
-199.78 %-201.09%
197.62 %-10,410.26%
-1.92 %-102.48%
77.35 %-594.91%
-15.63 %-127.21%
57.44 %-109.74%
-589.45 %+561.75%
-89.08 %-78.03%
-405.40 %-351.41%
161.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Guhan Pharmaceutical Group Co Stock analysis

What does Guhan Pharmaceutical Group Co do? Tus-Pharmaceutical Group Co., Ltd. generates revenue through the research and development, production, and sales of Chinese patent medicine and western medicine preparations. The company offers Chinese healthcare products, cold treatment medicines, and anti hyperlipemia medicines, alongside western medicine products such as clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection. Domestic markets are the primary sales channel for all products. The firm's revenue streams are derived from the sale of these pharmaceutical products to domestic customers. The company focuses on Chinese patent medicine, including healthcare products, cold treatment remedies, and anti hyperlipemia treatments. Western medicine preparations like clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection form a significant part of its product portfolio. These products are distributed exclusively within China, targeting domestic consumers and healthcare providers. Tus-Pharmaceutical Group Co., Ltd. serves domestic markets with its range of Chinese and western medicines. The company's product lines include Chinese healthcare products, cold treatment medicines, anti hyperlipemia medicines, and specific western medicine injections. Sales are conducted within China, with no mention of international distribution. The firm's revenue is generated through the direct sale of these pharmaceutical products to domestic buyers. Guhan Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guhan Pharmaceutical Group Co stock

FCF Conversion Rate (FCF/EBITDA) of Guhan Pharmaceutical Group Co is 39.29 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Guhan Pharmaceutical Group Co changed from 11.73 % to 39.29 %, representing a 235.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Guhan Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Guhan Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Guhan Pharmaceutical Group Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Guhan Pharmaceutical Group Co